Cargando…

Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial

BACKGROUND: The autonomic nervous system can be responsible for the initiation and maintenance of arrhythmias. Low-level tragus stimulation (LLTS), a noninvasive form of autonomic neuromodulation, has been shown to be effective in treating atrial fibrillation. We intended to treat frequent premature...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Cheng, Wu, Nan, Yang, Gang, Yang, Shu, Liu, Wenjie, Chen, Minglong, Po, Sunny S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591365/
https://www.ncbi.nlm.nih.gov/pubmed/37872628
http://dx.doi.org/10.1186/s13063-023-07713-2
_version_ 1785124206705377280
author Cai, Cheng
Wu, Nan
Yang, Gang
Yang, Shu
Liu, Wenjie
Chen, Minglong
Po, Sunny S.
author_facet Cai, Cheng
Wu, Nan
Yang, Gang
Yang, Shu
Liu, Wenjie
Chen, Minglong
Po, Sunny S.
author_sort Cai, Cheng
collection PubMed
description BACKGROUND: The autonomic nervous system can be responsible for the initiation and maintenance of arrhythmias. Low-level tragus stimulation (LLTS), a noninvasive form of autonomic neuromodulation, has been shown to be effective in treating atrial fibrillation. We intended to treat frequent premature ventricular complexes (PVCs) with LLTS. METHODS AND DESIGN: The present study will be a prospective multicenter, double-blind, randomized, controlled trial to assess the antiarrhythmic effects of LLTS on frequent PVCs in patients without structured heart disease (SHD). A total of 100 patients with PVC burden > 10% will be randomly assigned to the active or sham LLTS in 1:1 fashion and receive the proposed intervention for 6 months. The primary outcome is PVC burden at 6 months as assessed by 10 days of continuous ambulatory electrocardiographic monitoring. Secondary outcomes include heart rate variability (HRV), quality of life, skin sympathetic nerve activity, and inflammatory markers. Adverse events will also be recorded. DISCUSSION: The present trial will be the first to evaluate the effect of LLTS on frequent PVCs on patients without SHD. LLTS may serve as a low-cost, minimal-risk, and non-invasive alternative to conventional antiarrhythmic therapy. TRIAL REGISTRATION: ClinicalTrial.gov NCT04909528. Registered on 17 June 2021. World health organization trial registration data set was shown in Supplementary Table 1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07713-2.
format Online
Article
Text
id pubmed-10591365
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105913652023-10-24 Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial Cai, Cheng Wu, Nan Yang, Gang Yang, Shu Liu, Wenjie Chen, Minglong Po, Sunny S. Trials Study Protocol BACKGROUND: The autonomic nervous system can be responsible for the initiation and maintenance of arrhythmias. Low-level tragus stimulation (LLTS), a noninvasive form of autonomic neuromodulation, has been shown to be effective in treating atrial fibrillation. We intended to treat frequent premature ventricular complexes (PVCs) with LLTS. METHODS AND DESIGN: The present study will be a prospective multicenter, double-blind, randomized, controlled trial to assess the antiarrhythmic effects of LLTS on frequent PVCs in patients without structured heart disease (SHD). A total of 100 patients with PVC burden > 10% will be randomly assigned to the active or sham LLTS in 1:1 fashion and receive the proposed intervention for 6 months. The primary outcome is PVC burden at 6 months as assessed by 10 days of continuous ambulatory electrocardiographic monitoring. Secondary outcomes include heart rate variability (HRV), quality of life, skin sympathetic nerve activity, and inflammatory markers. Adverse events will also be recorded. DISCUSSION: The present trial will be the first to evaluate the effect of LLTS on frequent PVCs on patients without SHD. LLTS may serve as a low-cost, minimal-risk, and non-invasive alternative to conventional antiarrhythmic therapy. TRIAL REGISTRATION: ClinicalTrial.gov NCT04909528. Registered on 17 June 2021. World health organization trial registration data set was shown in Supplementary Table 1. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-023-07713-2. BioMed Central 2023-10-23 /pmc/articles/PMC10591365/ /pubmed/37872628 http://dx.doi.org/10.1186/s13063-023-07713-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Cai, Cheng
Wu, Nan
Yang, Gang
Yang, Shu
Liu, Wenjie
Chen, Minglong
Po, Sunny S.
Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title_full Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title_fullStr Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title_full_unstemmed Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title_short Transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (TREAT PVC): study protocol for a multi-center, double-blind, randomized controlled trial
title_sort transcutaneous electrical vagus nerve stimulation to suppress premature ventricular complexes (treat pvc): study protocol for a multi-center, double-blind, randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591365/
https://www.ncbi.nlm.nih.gov/pubmed/37872628
http://dx.doi.org/10.1186/s13063-023-07713-2
work_keys_str_mv AT caicheng transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT wunan transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT yanggang transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT yangshu transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT liuwenjie transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT chenminglong transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT posunnys transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial
AT transcutaneouselectricalvagusnervestimulationtosuppressprematureventricularcomplexestreatpvcstudyprotocolforamulticenterdoubleblindrandomizedcontrolledtrial